Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.56 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | INSR | P06213 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.53 |
| ▸ | TEK | Q02763 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394114 | 0.86 | KDR (0.57) | IRAK4MAP4K1KDRINSRPDGFRB | |
| SCHEMBL6394127 | 0.86 | KDR (0.57) | IRAK4MAP4K1KDRINSRPDGFRB | |
| SCHEMBL6399896 | 0.86 | KDR (0.57) | IRAK4MAP4K1KDRINSRPDGFRB | |
| SCHEMBL6395906 | 0.84 | KDR (0.60) | KDRINSRPDGFRBPDGFRATEK | |
| SCHEMBL6315627 | 0.81 | KDR (0.64) | IRAK4KDRINSRPDGFRBPDGFRA | |
| SCHEMBL6729217 | 0.80 | KDR (0.50) | IRAK4MAP4K1KDRINSRPDGFRB | |
| SCHEMBL6731642 | 0.78 | KDR (0.49) | IRAK4KDRINSRPDGFRBPDGFRA | |
| SCHEMBL6405264 | 0.78 | KDR (0.53) | IRAK4KDRINSRPDGFRBPDGFRA | |
| SCHEMBL6392417 | 0.78 | KDR (0.84) | KDRINSRPDGFRBPDGFRATEK | |
| SCHEMBL6731924 | 0.78 | KDR (0.53) | KDRINSRPDGFRBPDGFRATEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | IRAK4 408/4885MAP4K1 416/4885KDR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.